| ★ 01.11.2026 01:47 UTC | Eli Lilly stock surges as cheaper drugs unlock a bigger market | TheStreet |
| ★ 31.10.2026 22:30 UTC | After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock? | Motley Fool |
| ★ 31.10.2026 16:27 UTC | Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030 | Motley Fool |
| ★ 31.10.2026 13:27 UTC | Eli Lilly Rallies 11% in a Week as Q3 Sales Jump 39%, “Exceeding Our Prior Expectations” | TIKR |
| ★ 31.10.2026 09:08 UTC | OmniAb Inc (OABI) (Q3 2026) Earnings Call Highlights: Lilly Deal, Raised Guidance and a Busy ... | GuruFocus.com |
| ★ 31.10.2026 09:00 UTC | Eli Lilly Soars 11% in a Week on a $5.5 Billion Guidance Raise: “Beating on the Up” | TIKR |
| ★ 30.10.2026 23:17 UTC | What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Call | MarketBeat |
| ★ 30.10.2026 22:14 UTC | Novo Nordisk (NYSE:NVO) Could Be 61% Undervalued Following Rising GLP 1 Competition | Simply Wall St. |
| ★ 30.10.2026 20:04 UTC | BofA Makes Major Call on Eli Lilly Stock | GuruFocus.com |
| ★ 30.10.2026 20:02 UTC | Eli Lilly Stocks Rise 3.4% With Higher Sales but Lower EPS Guidance ▼ Guidance cut | GuruFocus.com |
| ★ 30.10.2026 19:13 UTC | LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today | Stocktwits |
| ★ 30.10.2026 18:35 UTC | Eli Lilly Is Now Worth as Much as Warren Buffett's Berkshire Hathaway. Can the Rally Keep Going? | Motley Fool |
| ★ 30.10.2026 17:33 UTC | Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs | 24/7 Wall St. |
| ★ 30.10.2026 16:50 UTC | Eli Lilly Seen Sustaining Obesity Growth, UBS Says | MT Newswires |
| ★ 30.10.2026 16:13 UTC | Eli Lilly raises earnings outlook as obesity drug demand drives strong growth, UBS says ▲ Guidance raised | Proactive |
| ★ 30.10.2026 16:04 UTC | Eli Lilly's GLP-1 Penetration, Volume Seen in Early Stages, RBC Capital Markets Says | MT Newswires |
| ★ 30.10.2026 15:14 UTC | OmniAb Q3 Earnings Call Highlights | MarketBeat |
| ★ 30.10.2026 13:52 UTC | UBS Raises Eli Lilly Price Target to $1,625 From $1,425, Maintains Buy Rating | MT Newswires |
| ★ 30.10.2026 13:20 UTC | BMO Raises Price Target on Eli Lilly to $1,650 From $1,400, Keeps Outperform Rating ▲ Upgrade | MT Newswires |
| 31.10.2026 05:05 UTC | Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3 | Stocktwits |
| 30.10.2026 21:03 UTC | OmniAb, Inc. Q3 2026 Earnings Call Summary | Moby |
| 30.10.2026 17:33 UTC | Stock Market: Google, Amazon, Intel, ServiceNow Trigger Tech Wreck, But Other Sectors Solid: Weekly Review | Investor's Business Daily |
| 30.10.2026 15:47 UTC | Fidelity’s Health Care ETF Holds the Biotechs XLV Skips. Retirees Should Know the Difference | 24/7 Wall St. |
| 30.10.2026 15:26 UTC | Prediction markets herald insider trading risks for private biotechs | Pharmaceutical Technology |
| 30.10.2026 15:07 UTC | VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach? | Zacks |
| 30.10.2026 14:45 UTC | Regeneron Soars 12% on Dupixent-Fueled Q3 Beat: “One of Our Strongest Years Ever” | TIKR |